Human Genome seeks FDA nod to market lupus drug

Says files Biologics License Application with FDA

Human Genome Sciences Inc said it has sought for U.S. regulatory approval to market its experimental lupus drug Benlysta that the biopharmaceutical company is co-developing with partner GlaxoSmithKline Plc.

Read full story